Levetiracetam concentrations in serum and in breast milk at birth and during lactation

Epilepsia. 2005 May;46(5):775-7. doi: 10.1111/j.1528-1167.2005.54804.x.

Abstract

Purpose: To study the pharmacokinetics of levetiracetam (LEV) at birth, during lactation, and in the nursed infant.

Methods: Eight consecutive breast-feeding women with epilepsy treated with LEV twice daily and their infants were studied.

Results: The mean umbilical cord serum/maternal serum ratio was 1.14 (range, 0.97-1.45) (n = 4). The mean milk/maternal serum concentration ratio was 1.00 (range, 0.76-1.33) at 3 to 5 days after delivery (n = 7). At sampling 2 weeks to 10 months after delivery (n = 5), it was similar (range, 0.85-1.38). At 3 to 5 days after delivery, the infants had very low LEV serum concentrations (<10-15 microM), a finding that persisted during continued breast-feeding. No malformations were detected, and in none of the infants did signs of adverse effects develop.

Conclusions: Our data indicate an extensive transfer of LEV from mother to fetus and into breast milk. However, breast-fed infants had very low LEV serum concentrations, suggesting a rapid elimination of LEV.

MeSH terms

  • Anticonvulsants / analysis*
  • Anticonvulsants / blood*
  • Anticonvulsants / pharmacokinetics
  • Breast Feeding*
  • Epilepsy / blood
  • Epilepsy / drug therapy*
  • Female
  • Fetal Blood / chemistry
  • Humans
  • Infant, Newborn / blood*
  • Lactation / blood*
  • Lactation / metabolism
  • Levetiracetam
  • Maternal-Fetal Exchange
  • Milk, Human / chemistry*
  • Milk, Human / metabolism
  • Parturition / blood*
  • Parturition / metabolism
  • Piracetam / analogs & derivatives*
  • Piracetam / analysis*
  • Piracetam / blood*
  • Piracetam / pharmacokinetics
  • Pregnancy
  • Pregnancy Complications / blood
  • Pregnancy Complications / drug therapy*
  • Pregnancy Complications / metabolism

Substances

  • Anticonvulsants
  • Levetiracetam
  • Piracetam